The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 27, 2019

Filed:

Feb. 24, 2016
Applicant:

Pitney Pharmaceuticals Pty Limited, Kogarah, New South Wales, AU;

Inventors:

Nobuharu Andoh, Kawachinagano, JP;

Osamu Sanpei, Kawachinagano, JP;

Tetsuo Toga, Kawachinagano, JP;

David Lawson Morris, Lugarno, AU;

Roger Aston, Manly, AU;

Koji Tanaka, Kawachinagano, JP;

Tomokazu Hino, Kawachinagano, JP;

Assignee:

Pitney Pharmaceuticals Pty Ltd., Claremont, Western Australia, AU;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/277 (2006.01); A61K 31/433 (2006.01); A61K 31/4245 (2006.01); A61K 31/5383 (2006.01); A61K 31/4196 (2006.01); A61K 31/437 (2006.01); A61K 31/381 (2006.01); A61P 35/00 (2006.01); A61K 31/40 (2006.01); A61K 31/415 (2006.01); A61K 31/4192 (2006.01); A61K 31/42 (2006.01); A61K 31/425 (2006.01); A61K 31/44 (2006.01); A61K 31/4433 (2006.01); A61K 31/4436 (2006.01); A61K 31/496 (2006.01); A61K 31/4965 (2006.01); A61K 31/505 (2006.01); A61K 31/535 (2006.01);
U.S. Cl.
CPC ...
A61K 31/277 (2013.01); A61K 31/381 (2013.01); A61K 31/40 (2013.01); A61K 31/415 (2013.01); A61K 31/4192 (2013.01); A61K 31/4196 (2013.01); A61K 31/42 (2013.01); A61K 31/425 (2013.01); A61K 31/4245 (2013.01); A61K 31/433 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/4433 (2013.01); A61K 31/4436 (2013.01); A61K 31/496 (2013.01); A61K 31/4965 (2013.01); A61K 31/505 (2013.01); A61K 31/535 (2013.01); A61K 31/5383 (2013.01); A61P 35/00 (2018.01);
Abstract

The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein Ris a hydrogen atom, an alkyl group and the like, R, R, and Rare the same or different and each is a hydrogen atom, an alkyl group and the like, Rand Rare the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Aris a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is —O—, —S—, —SO—, or —N(R)— wherein Ris a hydrogen atom, a (C-C)alkyl group and the like, or a pharmacologically acceptable salt thereof.


Find Patent Forward Citations

Loading…